Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.
Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.